

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
  
12  
13  
14  
15  
16  
17  
18  
19  
20

H.741

Introduced by Representatives Dame of Essex, Berry of Manchester, Fiske of  
Enosburgh, McFaun of Barre Town, and Troiano of Stannard

Referred to Committee on

Date:

Subject: Health; Alcohol and Drug Abuse Programs; ibogaine

Statement of purpose of bill as introduced: This bill proposes to establish a  
grant within the Department of Health's Alcohol and Drug Abuse Programs for  
the purpose of studying the effects of ibogaine as a treatment for opioid  
dependency in Vermont. The bill also proposes to establish a special fund for  
the purpose of funding the grant.

An act relating to funding ibogaine clinical trials

It is hereby enacted by the General Assembly of the State of Vermont:

Sec. 1. ALCOHOL AND DRUG ABUSE TREATMENT; IBOGAIN

(a) To the extent funds are available, the Department of Health's Alcohol  
and Drug Abuse Programs shall provide a three-year grant to study the effects  
of using ibogaine as a treatment for opioid dependency in Vermont. The  
Program shall award the grant to an individual or entity conducting clinical  
trials for substance abuse treatment among Vermont's opioid-dependent  
population. As a condition of receiving the grant, the successful applicant

1 shall be required to present findings and recommendations to the Governor,  
2 Senate Committee on Health and Welfare, and House Committee on Human  
3 Services at the conclusion of the clinical trials.

4 (b) The Ibogaine Clinical Trial Fund is established as a special fund  
5 pursuant to 32 V.S.A. chapter 7, subchapter 5 comprising dedicated revenues  
6 and public and private sources, such as gifts, grants, and donations, together  
7 with interest accruing to the Fund. The Commissioner of Health shall  
8 administer the Fund to support the grant for the ibogaine clinical trial. Any  
9 balance at the end of the fiscal year shall be carried forward in the Fund. The  
10 Fund shall cease to exist at the conclusion of the ibogaine clinical trial after the  
11 report has been submitted to the General Assembly, and any remaining balance  
12 shall revert to the General Fund.

13 Sec. 2. EFFECTIVE DATE

14 This act shall take effect on July 1, 2016.